title: Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Taif, Saudi Arabia cohort of the A1chieve study.
abstract: BACKGROUND
  The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents.
  
  
  METHODS
  Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for participants enrolled from Taif, Saudi Arabia.
  
  
  RESULTS
  A total of 791 subjects were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients were started on or were switched to biphasic insulin aspart (n = 238), insulin detemir (n = 325), insulin aspart (n = 9), basal insulin plus insulin aspart (n = 85) and other insulin combinations (n = 127). At baseline glycaemic control was poor for both insulin naïve (mean HbA1c: 9.7%) and insulin user (mean HbA1c: 9.8%) groups. After 24 weeks of treatment, both the study groups showed improvement in HbA1c (insulin naïve: -2.3%, insulin users: -2.6%). SADRs including major hypoglycaemic events did not occur in the study patients.
  
  
  CONCLUSIONS
  Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
authors.affiliation: Department of Internal Medicine, Al Rafie Hospital, Mekkah, Saudi Arabia.
authors.forename: Helmy
authors.initials: H
authors.lastname: El Gendy
authors.affiliation: Department of Internal Medicine, Alhada Armed Forces Hospital, Taif, Saudi Arabia.
authors.forename: Saud
authors.initials: S
authors.lastname: Al Sifri
authors.affiliation: Department of Internal Medicine, Bashrahil Hospital, Mekkah, Saudi Arabia.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Ghazy
keywords: A1chieve study; Saudi Arabia; Taif; insulin analogues; type 2 diabetes mellitus